Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Valeant Pharmaceuticals

News

Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

Shauna O'Brien Mar 16, 2015



Inside the Deal


In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.

The adjusted deal has been approved by the Boards of Directors of both companies.


Valeant And It’s M&A Strategy


Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.


Mutual Funds to Watch



The Bottom Line


If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book